糖尿病肾病与其他类型肾病患者肾组织中Smad1蛋白表达的比较

doi:10.16352/j.issn.1001-6325.2023.07.1097

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (7): 1097-1103.doi: 10.16352/j.issn.1001-6325.2023.07.1097

糖尿病肾病与其他类型肾病患者肾组织中Smad1蛋白表达的比较

陈纤纤^1,*, 冯烈¹, 周颖¹, 董向楠²

1.暨南大学附属第一医院内分泌与代谢科, 广东广州 510632;
2.暨南大学附属第一医院肾内科, 广东广州 510632

收稿日期:2022-05-05 修回日期:2023-02-27 出版日期:2023-07-05 发布日期:2023-07-05
通讯作者: ^*vickychen1982@126.com
基金资助:
中央高校基本科研业务费专项资金(11617317)

Comparison of the expression of Smad1 in renal tissues from patients with diabetic nephropathy and other types of renal diseases

CHEN Xianxian^1,*, FENG Lie¹, ZHOU Ying¹, DONG Xiangnan²

1. Endocrinological and Metabolic Department, the First Affiliated Hospital of Jinan University, Guangzhou 510632, China;
2. Nephrology Department, the First Affiliated Hospital of Jinan University, Guangzhou 510632, China

Received:2022-05-05 Revised:2023-02-27 Online:2023-07-05 Published:2023-07-05

摘要/Abstract

摘要： 目的比较糖尿病患者及其他类型肾病患者肾组织中Smad1蛋白表达量的差异,以及与相应尿Smad1蛋白含量的关系。方法收集通过肾活检确诊的糖尿病肾病患者(DN组9例)及其他类型肾病患者,包括局灶性肾小球硬化性肾病(FSGS组5例)、IgA肾病(IgA组12例)、微小病变型肾病(MNP组10例)的尿液及肾活检组织。ELISA以及免疫组化、免疫荧光等方法检测尿Smad1蛋白含量、肾活检组织Smad1蛋白的表达情况以及可受Smad1调节的胶原蛋白4(Col4)、α-平滑肌肌球蛋白(α-SMA)的表达情况。结果 DN组及其他3种肾病的患者均检测到尿中有Smad1蛋白的排泄,均高于健康人群(47例)(P<0.05)。4组肾病患者的肾活检组织不同区域(包括肾小球与肾小管区域)均有Smad1蛋白的表达,而DN组肾小管区域的Smad1蛋白的表达含量高于其他3组的水平(P<0.05)。4组肾病患者肾活检组织中不同区域均有Col4、α-SMA 蛋白与Smad1蛋白共同表达。结论不同肾病肾组织的不同区域都有Smad1蛋白表达的上调,与肾损伤有关。

关键词: 糖尿病肾病, 肾活检, Smad1蛋白, 胶原蛋白4(Col4), α-平滑肌肌球蛋白(α-SAM);

Abstract: Objective To compare urinary Smad1 and the protein content of Smad1 in renal tissues of patients with diabetic nephropathy (DN) and the patients with other types of nephropathy. Methods According to the result of renal biopsy, the patients were collected and divided into four groups as follows: the patients with diabetes nephropathy(DN group, 9 cases), with focal segmental glomerulosclerosis (FSGS group, 5 cases), with IgA nephropathy (IgA group, 12 cases) and with minimal change nephrosis (MNP group, 10 cases). Urinary Smad1 was examined using ELISA. The expression of Smad1, Col4 and α-SMA in renal tissues was detected by immunohistochemistry and immunofluorescence staining method. Results Urinary Smad1 can be detected in the DN group and there other groups (FSGS group, IgA group and MNP group). The urinary Smad1 from four groups was higher significantly than those from 47 healthy people with routine physical examination (P<0.05). The expression of Smad1 in different area of the renal tissues(the area of glomerulus and renal tubule) can be observed by immuno-histochemistry staining in the patients with four different types of nephropathy. The Smad1 expression in the renal tissue of the patients with diabetes nephropathy was higher than that of three other groups (P<0.05). The co-expression of Col4 and α-SMA with Smad1 in different area of the renal tissues (the area of glomerulus and renal tubule) was found. Conclusions The over-expression of Smad1 in different area of the renal tissues can be observed and is related with renal damage.

Key words: diabetes nephropathy, renal biopsy, Smad1 protein, type Ⅳ collagen protein(Col4), smooth muscle α-actin(α-SAM)

中图分类号:

R587.1

陈纤纤, 冯烈, 周颖, 董向楠. 糖尿病肾病与其他类型肾病患者肾组织中Smad1蛋白表达的比较[J]. 基础医学与临床, 2023, 43(7): 1097-1103.

CHEN Xianxian, FENG Lie, ZHOU Ying, DONG Xiangnan. Comparison of the expression of Smad1 in renal tissues from patients with diabetic nephropathy and other types of renal diseases[J]. Basic & Clinical Medicine, 2023, 43(7): 1097-1103.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/10.16352/j.issn.1001-6325.2023.07.1097

http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2023/V43/I7/1097

参考文献

[1] Abe H, Matsubara T, Iehara N, et al. Type Ⅳ collagen is transcriptionally regulated by Smad1 under advanced glycation end product (AGE) stimulation[J]. J Biol Chem, 2004, 279:14201-14206.
[2] Mima A, Arai H, Matsubara T, et al. Urinary Smad1 is a novel marker to predict later onset of mesangial matrix expansion in diabetic nephropathy[J]. Diabetes,2008, 57:1712-1722.
[3] Li Q, Feng L, Li J, et al. Urinary Smad1 is a new biomarker for diagnosis and evaluating the severity of diabetic nephropathy[J]. Endocrine, 2014,46:83-89.
[4] Fu WJ, Fang YG, Deng RT, et al. Correlation of high urinary Smad1 level with glomerular hyperfiltration in type 2 diabetes mellitus[J]. Endocrine, 2013,43:346-350.
[5] Tominaga T, Abe H, Ueda O, et al. Activation of bone morphogenetic protein 4 signaling leads to glomerulosclerosis that mimics diabetic nephropathy[J]. J Biol Chem,2011,286:20109-20116.
[6] Abe H, Tominaga T, Matsubara T, et al. Scleraxis modulates bon morphogenetic protein4 (BMP4)-Smad1 protein-smooth muscle-actin (SMA) signal transductionin in diabetic nephropathy[J]. J Biol Chem, 2012,287:20430-20442.
[7] Lan HY.Transforming growth factor-beta/Smad signalling in diabetic nephropathy[J]. Clin Exp Pharmacol Physiol, 2012, 39: 731-738.
[8] Moustakas A, Souchelnytskyi S, Heldin CH.Smad regulation in TGF-beta signal transduction[J]. J Cell Sci, 2001,114:4359-4369.
[9] Yamamoto T, Noble NA, Cohen AH, et al. Expression of transforming growth factor-beta isoforms in human glomerular diseases[J]. Kidney Int, 1996,49:461-469.
[10] Ji HK,Kim BK,Moon KC, et al. Activation of the TGF-beta/Smad signaling pathway in focal segmental glomerulosclerosis[J]. Kidney Int,2003,64:1715-1721.
[11] Cheon PH,Xu ZG,Sorae C,et al. Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy[J]. Nephrol Dial Transplant, 2003,18:1115-1121.
[12] Letizia Z, Anthony GW. Norden C, et al. A more tubulocentric view of diabetic kidney disease[J]. J Nephrol,2017, 30: 701-717.
[13] Upton PD, Long L, Trembath RC, et al. Functional characterization of bone morphogenetic protein binding sites and Smad1/5 activation in human vascular cells[J]. Mol Pharmacol,2008,73:539-552.
[14] Nakamura T, Ushiyama C, Suzuki S, et al, Urinary excretion of podocytes in patients with diabetic nephropathy[J]. Nephrol Dial Transplant, 2000,15:137913-137983.

[1]	邓九红, 郑超, 王声遥, 王心怡. 醋酸泼尼松对糖尿病肾病模型大鼠肾功能、肾脏炎性反应及AMPK/SIRT1信号通路的影响[J]. 基础医学与临床, 2022, 42(2): 243-248.
[2]	李梦婕, 柯本, 龙脉, 房向东. 线粒体融合蛋白Mfn2在糖尿病肾病中作用的研究进展[J]. 基础医学与临床, 2021, 41(12): 1823-1827.
[3]	孙凤起, 武韧, 常贵全, 李鸿珠. 肾小球系膜细胞增殖在糖尿病肾病肾小球硬化中作用的研究进展[J]. 基础医学与临床, 2021, 41(10): 1510-1513.
[4]	谢飞, 周美兰. 羟基红花黄色素A抑制高糖诱导的小鼠肾足细胞损伤[J]. 基础医学与临床, 2021, 41(1): 27-32.
[5]	郭红宝, 刘友霞, 贾俊亚, 闫铁昆. miR-451通过Akt负向调控糖尿病肾病患者组织上皮间质转分化[J]. 基础医学与临床, 2020, 40(4): 469-472.
[6]	张娅, 黄文辉, 侯智敏, 刘菊香, 刘静. 厄贝沙坦减轻糖尿病肾病大鼠肾损伤[J]. 基础医学与临床, 2020, 40(4): 506-511.
[7]	杨李莉, 郭志新, 冯劲宜, 宋英伦, 石文娇. 重组球形脂联素减轻糖尿病小鼠肾脏损伤[J]. 基础医学与临床, 2020, 40(4): 518-522.
[8]	李思倩朱子璇文煜冰庄俊玲陈丽萌李雪梅李明喜. 多发性骨髓瘤管型肾病和肾淀粉样变性的临床特征及预后分析[J]. 基础医学与临床, 2019, 39(10): 1483-1487.
[9]	邱维张薇陶建瓴王海云郑法雷李雪梅. 倍半萜内酯减轻糖尿病小鼠胰岛素抵抗及早期肾损伤[J]. 基础医学与临床, 2018, 38(9): 1292-1297.
[10]	李爱玲彭睿孙艳彭惠民易红张政. 长链非编码RNA-1700020I14Rik对高糖培养下肾系膜细胞纤维化的影响[J]. 基础医学与临床, 2017, 37(6): 781-785.
[11]	文利陈蕾孙一瑄段青蕊魏礼江周琴彭惠民张政. 柚皮素通过抑制TGF-β1/smad信号传导通路缓解糖尿病肾病大鼠肾损伤[J]. 基础医学与临床, 2016, 36(7): 896-901.
[12]	陈艳霞曹莉萍房向东涂卫平. 幽门螺杆菌感染与肾脏相关性疾病[J]. 基础医学与临床, 2014, 34(8): 1150-1153.
[13]	周敏张晓良. 微小RNAs在糖尿病肾病中的作用[J]. 基础医学与临床, 2014, 34(5): 711-714.
[14]	黄炜徐玲徐勇周雪琴彭娟. SUMO化修饰对高糖诱导的大鼠肾系膜细胞IκB/NF-κB信号的影响[J]. 基础医学与临床, 2014, 34(12): 1689-1693.
[15]	刘瑞霞郭兵肖瑛石明隽王圆圆李晓颖张国忠. SnoN和Smad2/3信号蛋白与糖尿病大鼠肾小管-间质纤维化的关系[J]. 基础医学与临床, 2010, 30(9): 944-951.

糖尿病肾病与其他类型肾病患者肾组织中Smad1蛋白表达的比较

Comparison of the expression of Smad1 in renal tissues from patients with diabetic nephropathy and other types of renal diseases

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价